Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome.
Deepak Ben VangalaSwetlana Ladigan-BaduraChristoph EngelRobert HüneburgClaudia PerneKarolin BuckschJacob NattermannVerena Steinke-LangeNils RahnerJürgen WeitzMatthias KloorJudith TomannAli CanbayHuu-Phuc NguyenChristian P StrassburgGabriele MösleinMonika MorakElke Holinski-FederReinhard BüttnerStefan AretzMarkus LöfflerWolff SchmiegelChristian PoxKarsten Schulmannnull nullPublished in: International journal of cancer (2021)
Small bowel cancer (SBC) is the malignancy with the highest standardized incidence ratio in Lynch syndrome (LS) patients. Of all SBCs, about 50% are duodenal cancers (DCs), therefore being accessible by esophago-gastro-duodenoscopy (EGD) for surveillance. We asked whether early detection of DC is possible for LS patients undergoing surveillance by EGD and if surveillance should be limited to specific subgroups. Data for LS patients with DC were retrieved from the registry of the German Consortium for Familial Intestinal Cancer. Patients undergoing active surveillance by EGDs (surveillance group) were compared to those who did not (nonsurveillance group) regarding tumor stage at diagnosis. Union for International Cancer Control stages I-IIA were defined as early stage disease and IIB-IV as advanced stage disease. Statistical analysis was performed using Fisher's exact test. Among 2015 patients with pathogenic variants in any mismatch-repair-gene, 47 patients with 49 DCs were identified. In 10% of cases, patients were under 35 years at diagnosis; family and personal tumor history did not correlate with DC diagnosis. Pathogenic germline variants in MSH6, PMS2 or EPCAM were present in 10% of patients. Statistical analysis could be performed on 13 DC patients in the surveillance group and 14 in the nonsurveillance group. Early detection was possible for 71% of patients in the surveillance group and 29% of patients in the nonsurveillance group (P = .021). Early detection of DC by EGD in LS patients is feasible regardless of family history, mutational status and should start no later than 25 years of age.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- early stage
- patients undergoing
- prognostic factors
- dna damage
- squamous cell carcinoma
- young adults
- immune response
- dendritic cells
- patient reported outcomes
- early onset
- papillary thyroid
- deep learning
- gene expression
- machine learning
- oxidative stress
- locally advanced
- squamous cell
- lymph node metastasis